161 related articles for article (PubMed ID: 26496242)
1. Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia.
Neumann T; Benajiba L; Göring S; Stegmaier K; Schmidt B
J Med Chem; 2015 Nov; 58(22):8907-19. PubMed ID: 26496242
[TBL] [Abstract][Full Text] [Related]
2. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
[TBL] [Abstract][Full Text] [Related]
4. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibitors of glycogen synthase kinase 3.
Meijer L; Flajolet M; Greengard P
Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
[TBL] [Abstract][Full Text] [Related]
7. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.
Banerji V; Frumm SM; Ross KN; Li LS; Schinzel AC; Hahn CK; Kakoza RM; Chow KT; Ross L; Alexe G; Tolliday N; Inguilizian H; Galinsky I; Stone RM; DeAngelo DJ; Roti G; Aster JC; Hahn WC; Kung AL; Stegmaier K
J Clin Invest; 2012 Mar; 122(3):935-47. PubMed ID: 22326953
[TBL] [Abstract][Full Text] [Related]
8. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner FF; Benajiba L; Campbell AJ; Weïwer M; Sacher JR; Gale JP; Ross L; Puissant A; Alexe G; Conway A; Back M; Pikman Y; Galinsky I; DeAngelo DJ; Stone RM; Kaya T; Shi X; Robers MB; Machleidt T; Wilkinson J; Hermine O; Kung A; Stein AJ; Lakshminarasimhan D; Hemann MT; Scolnick E; Zhang YL; Pan JQ; Stegmaier K; Holson EB
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515000
[TBL] [Abstract][Full Text] [Related]
9. GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia.
Guezguez B; Almakadi M; Benoit YD; Shapovalova Z; Rahmig S; Fiebig-Comyn A; Casado FL; Tanasijevic B; Bresolin S; Masetti R; Doble BW; Bhatia M
Cancer Cell; 2016 Jan; 29(1):61-74. PubMed ID: 26766591
[TBL] [Abstract][Full Text] [Related]
10. Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.
Darrington RS; Campa VM; Walker MM; Bengoa-Vergniory N; Gorrono-Etxebarria I; Uysal-Onganer P; Kawano Y; Waxman J; Kypta RM
Int J Cancer; 2012 Sep; 131(6):E872-83. PubMed ID: 22539113
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glycogen synthase kinase 3beta during heart failure is protective.
Hirotani S; Zhai P; Tomita H; Galeotti J; Marquez JP; Gao S; Hong C; Yatani A; Avila J; Sadoshima J
Circ Res; 2007 Nov; 101(11):1164-74. PubMed ID: 17901358
[TBL] [Abstract][Full Text] [Related]
12. Fine-Tuning of the RIG-I-Like Receptor/Interferon Regulatory Factor 3-Dependent Antiviral Innate Immune Response by the Glycogen Synthase Kinase 3/β-Catenin Pathway.
Khan KA; Dô F; Marineau A; Doyon P; Clément JF; Woodgett JR; Doble BW; Servant MJ
Mol Cell Biol; 2015 Sep; 35(17):3029-43. PubMed ID: 26100021
[TBL] [Abstract][Full Text] [Related]
13. The Wnt pool of glycogen synthase kinase 3beta is critical for trophic-deprivation-induced neuronal death.
Hongisto V; Vainio JC; Thompson R; Courtney MJ; Coffey ET
Mol Cell Biol; 2008 Mar; 28(5):1515-27. PubMed ID: 18195042
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors.
Shen L; Prouty C; Conway BR; Westover L; Xu JZ; Look RA; Chen X; Beavers MP; Roberts J; Murray WV; Demarest KT; Kuo GH
Bioorg Med Chem; 2004 Mar; 12(5):1239-55. PubMed ID: 14980636
[TBL] [Abstract][Full Text] [Related]
15. Expression and regulation of glycogen synthase kinase 3 in human neutrophils.
Giambelluca MS; Cloutier N; Rollet-Labelle E; Boilard E; Pouliot M
Int J Biochem Cell Biol; 2013 Nov; 45(11):2660-5. PubMed ID: 24035907
[TBL] [Abstract][Full Text] [Related]
16. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.
Kulkarni NH; Onyia JE; Zeng Q; Tian X; Liu M; Halladay DL; Frolik CA; Engler T; Wei T; Kriauciunas A; Martin TJ; Sato M; Bryant HU; Ma YL
J Bone Miner Res; 2006 Jun; 21(6):910-20. PubMed ID: 16753022
[TBL] [Abstract][Full Text] [Related]
17. Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3.
Atilla-Gokcumen GE; Williams DS; Bregman H; Pagano N; Meggers E
Chembiochem; 2006 Sep; 7(9):1443-50. PubMed ID: 16858717
[TBL] [Abstract][Full Text] [Related]
18. Oxazolo[5,4-f]quinoxaline-type selective inhibitors of glycogen synthase kinase-3α (GSK-3α): Development and impact on temozolomide treatment of glioblastoma cells.
Hasyeoui M; Lassagne F; Erb W; Nael M; Elokely KM; Chaikuad A; Knapp S; Jorda A; Vallés SL; Quissac E; Verreault M; Robert T; Bach S; Samarat A; Mongin F
Bioorg Chem; 2023 May; 134():106456. PubMed ID: 36913879
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
